Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7517287 | 0.76 | ESR1 (0.49) | SMN1; SMN2ESR1MAPK1LMNAL3MBTL1 | |
| SCHEMBL5449273 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNA | |
| SCHEMBL2995460 | 0.72 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNA | |
| SCHEMBL19280067 | 0.72 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL15070002 | 0.68 | SMN1; SMN2 (0.44) | SMN1; SMN2 | |
| SCHEMBL14369404 | 0.65 | ESR1 (0.41) | SMN1; SMN2ESR1MAPK1LMNAL3MBTL1 | |
| SCHEMBL2790791 | 0.65 | — | — | |
| SCHEMBL18878029 | 0.65 | — | — | |
| SCHEMBL15417801 | 0.64 | MEN1 (0.46) | SMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL18185800 | 0.64 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007128672-A1 | SUBSTITUTED HEXAHYDRO-1,4-DIAZEPIN-5-ONES AND COMPOSITIONS STABILIZED THEREWITH | CIBA HOLDING INC. (CH) | 2007-11-15 | — | — | WO | claimed |
| US-20070256352-A1 | Substituted hexahydro-1,4-diazepin-5-ones and compositions stabilized therewith | WOOD MERVIN G | 2007-11-08 | — | — | US | claimed |
| WO-2007128672-A1 | SUBSTITUTED HEXAHYDRO-1,4-DIAZEPIN-5-ONES AND COMPOSITIONS STABILIZED THEREWITH | CIBA HOLDING INC. (CH) | 2007-11-15 | — | — | WO | disclosed |
| US-20070256352-A1 | Substituted hexahydro-1,4-diazepin-5-ones and compositions stabilized therewith | WOOD MERVIN G | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070256352-A1 | Substituted hexahydro-1,4-diazepin-5-ones and compositions stabilized therewith | CRY1, GPX4, CAND1 | SMN1; SMN2 1627/4885ESR1 3222/4885MAPK1 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.